Kashyap Patel, MD: Misconceptions About Biosimilars

Kashyap Patel, MD, discusses the prevailing misconceptions about biosimilars among oncologists. 
June 21, 2019


That's very interesting question, because the prescribers are still not aware of the rigorous pathway—there’s something called the totality of the evidence that’s undergone in terms of evaluating the molecule. Many prescribers even now think that biosimilars and generics are the same. There’s a significant difference and a significant cost difference in developing a biosimilar, so there are a lot of misconceptions prevailing among my colleagues as well as many prescribers. As a chairman of the biosimilars committee at the [Community Oncology Alliance, COA], we’re trying to help address the knowledge gap and the needs assessment in the biosimilars market.


Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2019 Intellisphere, LLC. All Rights Reserved.